Man up.

Gardasil is one the greatest tools in cancer prevention ever created. So how are we doing on the uptake? Not so good it turns out. This large cross sectional study conducted from 2013-2014 sampled 1868 men ages 18 to 59 to assess HPV prevalence (via penile swab) in conjunction with vaccination rates (via interview). The overall genital HPV prevalence was a whopping 45% with over half of those being a known high-risk strain. Among vaccine-eligible men, the vaccination rate was only 1 in 10. Beyond the obvious detriment to the herd immunity necessary for optimal cervical cancer prevention, this failure to vaccinate is likely to result in far fewer anogenital and oropharyngeal cancer preventions in men. Boy oh boy.